Matches in Wikidata for { <http://www.wikidata.org/entity/Q37279632> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- Q37279632 description "article científic" @default.
- Q37279632 description "article scientifique" @default.
- Q37279632 description "articolo scientifico" @default.
- Q37279632 description "artigo científico" @default.
- Q37279632 description "artículu científicu espublizáu en 2016" @default.
- Q37279632 description "bilimsel makale" @default.
- Q37279632 description "scientific article published on 19 September 2016" @default.
- Q37279632 description "vedecký článok" @default.
- Q37279632 description "vetenskaplig artikel" @default.
- Q37279632 description "videnskabelig artikel" @default.
- Q37279632 description "vědecký článek" @default.
- Q37279632 description "wetenschappelijk artikel" @default.
- Q37279632 description "wissenschaftlicher Artikel" @default.
- Q37279632 description "наукова стаття, опублікована у вересні 2016" @default.
- Q37279632 description "научни чланак" @default.
- Q37279632 description "مقالة علمية نشرت في 19 سبتمبر 2016" @default.
- Q37279632 name "Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea" @default.
- Q37279632 name "Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea" @default.
- Q37279632 name "Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea" @default.
- Q37279632 type Item @default.
- Q37279632 label "Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea" @default.
- Q37279632 label "Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea" @default.
- Q37279632 label "Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea" @default.
- Q37279632 prefLabel "Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea" @default.
- Q37279632 prefLabel "Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea" @default.
- Q37279632 prefLabel "Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea" @default.
- Q37279632 P1433 Q37279632-A1287269-AFDA-4DAE-8F9E-48C0AEB1F328 @default.
- Q37279632 P1476 Q37279632-F33FA79F-F141-4865-B871-6F458156306C @default.
- Q37279632 P2093 Q37279632-494DFDDB-8264-4CE0-A1AE-B51B281F3B9B @default.
- Q37279632 P2093 Q37279632-4A907408-7E22-4733-8B07-7C09DF676071 @default.
- Q37279632 P2093 Q37279632-539CD575-B6C8-4528-86CD-6CD92A3F5DB7 @default.
- Q37279632 P2093 Q37279632-AF302FE1-0D78-45DB-B486-4E326ED9B710 @default.
- Q37279632 P275 Q37279632-397a4ef7-818b-465c-be52-7367859903b5 @default.
- Q37279632 P2860 Q37279632-00D942E6-B9BE-4BA9-B89A-0500B6FF943E @default.
- Q37279632 P2860 Q37279632-4CFECFD5-1F3E-4C36-B84F-ECF765155EC5 @default.
- Q37279632 P2860 Q37279632-827D762A-5114-4F85-8296-9F2F6D6AFF02 @default.
- Q37279632 P2860 Q37279632-86AF2E84-DC6E-4A3E-9CF6-06D1BCDA1A3C @default.
- Q37279632 P2860 Q37279632-CDAB289F-F0AE-4D42-BF52-713125E8DACF @default.
- Q37279632 P2860 Q37279632-D3F956D1-726B-4513-9E24-253373442FE5 @default.
- Q37279632 P2860 Q37279632-DC251D73-8F39-467E-A15E-CDBE8D7E1FE0 @default.
- Q37279632 P304 Q37279632-134B62F1-268C-4A76-9C4D-41A5564CA707 @default.
- Q37279632 P31 Q37279632-11E14337-A256-49DB-9283-1F49D68A9A8D @default.
- Q37279632 P356 Q37279632-D043AFA9-E0F5-46DF-B3A8-E4F2469D2F48 @default.
- Q37279632 P407 Q37279632-374A2C01-47EB-4AB3-A0ED-782C73040B52 @default.
- Q37279632 P478 Q37279632-B9051ACC-A0FC-43E5-8E53-74F54F83E9D1 @default.
- Q37279632 P50 Q37279632-E6DA67CC-3AAE-4164-A3A0-4AC6798003F5 @default.
- Q37279632 P577 Q37279632-68DC18EC-B232-48B2-B776-ABC5B599DFEA @default.
- Q37279632 P6216 Q37279632-f3279c0e-4293-4526-8e8f-600ceaed10a3 @default.
- Q37279632 P698 Q37279632-E6C3E6DF-0258-47A8-949F-47A6A3B88292 @default.
- Q37279632 P921 Q37279632-96D3B076-A9B1-4F52-B87D-EADDF60CE3BB @default.
- Q37279632 P921 Q37279632-BACD15B8-89AC-46FF-BC82-7C90CFB69454 @default.
- Q37279632 P932 Q37279632-A1F41AF2-2EA0-41F8-BB04-FD798B6DC00A @default.
- Q37279632 P356 CEOR.S110553 @default.
- Q37279632 P698 27698565 @default.
- Q37279632 P1433 Q5133862 @default.
- Q37279632 P1476 "Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea" @default.
- Q37279632 P2093 "Gabriel Tremblay" @default.
- Q37279632 P2093 "Ilias Kontoudis" @default.
- Q37279632 P2093 "Jeongae Park" @default.
- Q37279632 P2093 "Unnati Majethia" @default.
- Q37279632 P275 Q18810331 @default.
- Q37279632 P2860 Q35237226 @default.
- Q37279632 P2860 Q35721526 @default.
- Q37279632 P2860 Q36322815 @default.
- Q37279632 P2860 Q42653377 @default.
- Q37279632 P2860 Q47441440 @default.
- Q37279632 P2860 Q89242077 @default.
- Q37279632 P2860 Q89243120 @default.
- Q37279632 P304 "485-493" @default.
- Q37279632 P31 Q13442814 @default.
- Q37279632 P356 "10.2147/CEOR.S110553" @default.
- Q37279632 P407 Q1860 @default.
- Q37279632 P478 "8" @default.
- Q37279632 P50 Q47502144 @default.
- Q37279632 P577 "2016-09-19T00:00:00Z" @default.
- Q37279632 P6216 Q50423863 @default.
- Q37279632 P698 "27698565" @default.
- Q37279632 P921 Q12859063 @default.
- Q37279632 P921 Q884 @default.
- Q37279632 P932 "5034912" @default.